1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow IO Biotech: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) IO102-IO103, Pembrolizumab - Metastatic Melanoma, Unresectable Melanoma | Phase 3 | Active not recruiting | IO Biotech | 407 | 2022-05-17 | 2025-08-28 |
Melanoma (1)
pembrolizumab (1)
Australia (1) · Belgium (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · South Africa (1) · Spain (1) · Turkey (Türkiye) (1) · United Kingdom (1)